// App-Quantinova.ai

502 : ETNA (Evaluating Treatment with Neoadjuvant Abraxane) Randomized Phase III Study Comparing Neoadjuvant Nab-Paclitaxel (nab-P) Versus Paclitaxel (P) Both Followed by Anthracycline Regimens in Women with HER2-Negative High-Risk Breast Cancer: A MICHELANGO Study in collaboration with GEICAM and BCRC-WA

Researchers

Presenter

  • Luca Gianni

Principal Investigators

  • Antonio Anton

  • Lourdes Calvo

  • Giancarlo Bisagni

  • Begona Bermejo

  • Vladimir Semiglazov

  • Marc Thill

  • Jose Ignacio Chacon

  • Arlene Chan

  • Serafin Morales

  • Isabel Alvarez

  • Arrate Plazaola

  • Milvia Zambetti

  • Andrew D. Redfern

  • Christian Dittrich

  • Rebecca Alexandra Dent

  • Domenico Magazzu'

  • Pinuccia Valagussa

  • Ignacio Tusquets

Medical Centers

  • Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy

  • Department of Oncology, University Hospital of Udine, Udine, Italy

  • H. Universitario Miguel Servet, Zaragoza, Spain

  • Complejo Hospitalario Universitario de A Coruna, A Coruna, Spain

  • Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy

  • Hospital Clinico Universitario, Valencia, Valencia, Spain

  • NN Petrov Research Institute of Oncology, St Petersburg, Russia

  • Agaplesion Markus Krankenhaus, Klinik fur Gynakologie und Geburtshilfe, Frankfurt am Main, Germany

  • Hospital Virgen de la Salud, Toledo, Spain

  • Breast Cancer Research Centre - WA & Curtin University, Perth, Australia

  • Medical Oncology Department, Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain

  • Hospital Donostia, San Sebastian, Spain

  • Onkologikoa, San Sebastian, Spain

  • San Raffaele Hospital, Milan, Italy

  • Royal Perth Hospital, Perth, WA, Australia

  • Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna), Kaiser Franz Josef-Spital, Vienna, Austria, Vienna, Austria

  • National Cancer Centre Singapore, Singapore, Singapore

  • Fondazione Michelangelo, Milan, Italy

  • Fondazione Michelangelo, Milan, Italy

  • Hospital Del Mar Sericio Oncologia Medica, Barcelona, Spain

Locations

  • Italy

  • Austria

  • Singapore

  • Spain

  • Germany

  • Australia

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Paclitaxel

  • Protein-bound paclitaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT01822314

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved